Niflumic acid-13C6

Niflumic acid-13C6 is the 13C6 labeled Niflumic acid. Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

Product Specifications

CAS Number

[1325559-33-8]

UNSPSC

12352005

Hazard Statement

H301, H312+H332, H315, H319, H335

Target

Chloride Channel; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/niflumic-acid-13c6.html

Purity

99.8

Solubility

10 mM in DMSO

Smiles

O=C(C1=CC=CN=C1N[13C]2=[13CH][13CH]=[13CH][13C](C(F)(F)F)=[13CH]2)O

Molecular Formula

C7 13C6H9F3N2O2

Molecular Weight

288.17

Precautions

H301, H312+H332, H315, H319, H335

References & Citations

[1]Criddle, D.N., et al., Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol, 1997. 120 (5) : p. 813-8.|[2]Jabeen, T., et al., Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr, 2005. 61 (Pt 12) : p. 1579-86.|[3]Picollo, A., et al., Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J Membr Biol, 2007. 216 (2-3) : p. 73-82.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.